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http:WHAT THIS PAPER ADDS
At our center, laser ablation as a minimally invasive method has shown, over the short term, promise in the
treatment of congenital extratruncular venous malformations. In this study, the results show that endovenous
laser ablation is a minimally invasive treatment with the advantages of safety, effectiveness, and simplicity in
ameliorating symptoms associated with venous malformations in appropriately selected patients.Objective/Background: Over the short term, endovenous laser ablation (EVLA) has been found to be safe and
effective for endovenous ablation in extratruncular venous malformations (EVMs). We report our experiences in
percutaneous ultrasound (US)-guided treatment of congenital EVMs with respect to effectiveness and safety over
the mid-term.
Methods: This was a retrospective analysis of a collected database of consecutive US-guided intralesional diode
laser treatments of congenital EVMs (2007e2013). A consecutive series of 164 patients (86 women/girls [53%]
and 78 men/boys [46%], aged 1.5e68.0 years [mean age 20.78 years]) were treated using EVLA for congenital
EVMs at our institution. All of the patients were symptomatic. The primary outcomes for assessing safety were
mortality and morbidity, including laser-related adverse events, thrombotic events, and important nerve or vessel
injuries, and so on. Effectiveness was assessed according to reduction of the mass, the absence of pain, and
technical success.
Results: One hundred and ninety procedures were undertaken in 164 patients, achieving a 100% immediate
technical success rate. Most complications were minor and improved quickly, except in one patient, who suffered
a peroneal nerve injury. Spot skin burn injuries occurred in one procedure (0.53%). Paresthesia in the treated
area was noted after 15 procedures (7.89%). For complaints related to swelling, cosmetic outcomes, and pain,
the clinical success rates were 65.71%, 68.97% and 97.74%, respectively. After a mean follow-up of 23.91 months,
no patient suffering from pain, hemorrhage, or limited range of motion had returned with recurrent symptoms
after initial successful treatment (resolved). Recurrence rates in patients with heavy sensation, swelling, and
deformity were 6.89% (two of 29), 7.41% (two of 27), and 11.11% (one of nine), respectively. One hundred and
twelve (59.00%) treated lesion areas were classiﬁed as “excellent”, 59 lesions (31.00%) were “good”, and 19
lesions (10.00%) were “fair” using duplex US imaging at the ﬁnal follow-up visit.
Conclusions: EVLA is a minimally invasive treatment with the advantages of safety, effectiveness, and simplicity in
ameliorating symptoms associated with EVMs in appropriately selected patients.
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Venous malformations (VMs) are congenital, comprise two-
thirds of vascular malformations, and are formed from ve-
nules and large veins. Based on the Hamburg Classiﬁcation
System,1 congenital VMs are appropriately classiﬁed into
extratruncular VM (EVM) or truncular VM using criteria that
take into account the underlying anatomical, histological,
pathophysiological and hemodynamic status of the defects,
which are arise at different embryonic stages. The EVM
Table 1. Baseline clinical and demographic characteristics of 164
patients treated with endovenous laser ablation.
EVMs
Limited Inﬁltrating Total
Sex (n)
Male 17 61 78
Female 19 67 86
Age (y), mean 18.47 21.32 20.78
Lesion location (n)
Shoulder 2 7 9
Chest and abdomen 2 9 11
Back 0 5 5
Forearm 6 12 18
Lower extremity 15 83 98
Foot 5 14 19
Hips 2 9 11
Perineum 1 7 8
Fingers 2 13 15
Temporalis 1 0 1
Symptoms and signs (n)
Pain 21 112 133
Heavy sensation 9 68 77
Limited range of motion 2 9 11
Hemorrhage 0 6 6
Swelling 17 88 105
Deformity 2 27 29
Note. EVM ¼ extratruncular venous malformation.
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in size with the patient; it may undergo accelerated growth
during adolescence, pregnancy, surgery, or trauma. The
truncular subtype preserves the embryonic characteristics
of the mesenchymal cells, along with the potential to grow
and proliferate, resulting in a high risk of recurrence. Their
speciﬁc biological characteristics make it the most difﬁcult
lesions to treat, posing a major clinical challenge.
The clinical manifestations of EVMs include venous stasis,
ischemia, skeletal anomalies, coagulopathy, disseminated
intravascular coagulation, and so on. Surgical resection re-
mains the only solution for “cure” of EVMs; however,
generally, it requires surgical excess with high morbidity
(e.g., excessive blood loss, adjacent nerve damage, move-
ment limitations, scars). Incomplete resection of the lesion
will result in higher risks of recurrence.2,3 Repeated foam
sclerotherapy for the treatment of EVMs is not ideal.
Because most vascular malformations have complicated
venous networks with irregular lumens, it is difﬁcult to
control the dosage of sclerosing reagents owing to their
progressive dilution and irregular distribution in the vessels.
Thrombotic occlusion with mild endothelial injury caused by
irritants has been associated with recanalization rates
ranging from 1% to 15%.4 Even worse, the irritants may
enter into the systematic circulation during sclerotherapy
and induce cardiovascular events.5
As a minimally invasive method, laser ablation has shown
great success in the treatment of saphenous vein insufﬁ-
ciency and tributary varices. The ﬁbrotic obliteration of the
lumen caused by laser ablation has achieved an overall
long-term closure rate of 94e97%.6e9 Histological analysishas shown that the main damage occurs along the path of
the laser’s contact with the wall, implying that the primary
mechanism of action of endovenous laser ablation (EVLA) is
thermal injury caused by direct contact and by the heated
bubbles of steam created.10e12 It has also shown promise,
over the short-term, in the treatment of congenital EVMs.13
In this study, a consecutive series of 164 patients (86
women/girls [53%] and 78 men/boys [46%]) being treated
with EVLA for congenital EVMs at our institution from May
2007 to February 2013 were analyzed retrospectively. This
article recounts our experiences with EVLA in the treatment
of EVMs, and evaluates its efﬁcacy and safety over the mid-
term.
MATERIALS AND METHODS
Patient proﬁles and treatment procedures
We reviewed the records of all of patients who received
laser ablation treatment. All of the patients signed informed
consent forms, and the protocols of this study were
approved by the ethics committee of the 9th People’s
Hospital. The clinical data of the patients are listed in
Table 1, and a database was set up using a spreadsheet.
Data included the extent of the lesion, different anatomical
sites, the age of the patient, and the extent of clearance of
the lesion as the treatment’s end point. The main criterion
for study inclusion was a diagnosis of EVM according to The
Hamburg Classiﬁcation System.
Inclusion criteria were as follows:
 lesions were visible on ultrasound
 lesions (size, anatomical location, or both) ranged widely,
were dispersing or localized, or the patient was unwilling
to undergo surgical treatment
 low-ﬂow lesions, resulting in no change after
conservative management
 declining quality of life for patients with swelling, pain
and other symptoms.
Exclusion criteria included contraindications, such as
ﬁbrinogen levels <1.0 (normal range 2e4 g/L), or intoler-
ance of anesthesia, and deep lesions not visible on ultra-
sound (US).Pre-procedure patient care and anesthesia
For treatment planning, all of the patients had magnetic
resonance imaging (MRI) of the affected areas, and only
patients with US-visible lesions were selected for laser
ablation. All of the patients were treated under general,
epidural, lumbar, or local anesthesia.Laser technique
Only the portions of the lesions visible on US were treated.
For small, localized lesions, we attempted to treat the entire
lesion in one session. For large and diffused lesions, only
parts of the lesions, chosen by patient direction and visible
protrusion of the swelling, were treated per session.
560 G. Liu et al.The procedure has been previously described, in detail,
by Lu et al.13 In brief, percutaneous access was established
by US guidance with a 16- or 18-gauge intravenous catheter,
or a 3-F sheath. It was conﬁrmed that placement of the
catheter was accurate by the clear back-ﬂow of blood after
puncture. A coaxial 600-mm laser ﬁber (810 nm wavelength;
DIOMED, Cambridge, UK) was inserted into the lesions,
avoiding superﬁcial vessels. An 810-nm diode laser was
used to generate sufﬁcient heat to cause thermal damage
to the venous endothelium. The sheath, or catheter, was
withdrawn to expose 2e3 cm of the distal laser ﬁber. The
laser energy ranged from 10 to 13 W (1-second pulses
separated by 1-second intervals), depending on the size of
the lesions. Meanwhile, the pulse duration of each second
was triggered by a foot pedal. In this series, US guidance
was used not only to conﬁrm the position of the laser ﬁber,
but also to monitor the formation and distribution of
microbubbles in real time. The aim of selecting the appro-
priate level of energy was to treat the variously sized
venous channels effectively and to lower the risk of
nontarget thrombosis.
The ﬁber was slowly withdrawn toward the border of
lesion, with the microbubbles ﬁlling the channels. If the
microbubbles were not sufﬁciently in contact with the vein
walls, the number of pulses was increased to generate more
energy. If bubbles were seen to move towards known
outﬂow veins, treatment was stopped in that channel to
avoid the risk of systemic embolization. If the laser ﬁber was
too superﬁcial to the skin, it was an indicator of early skin
burns. During the procedure, manual compression was
applied to the treated area, which improved the vessel wall
apposition around the laser ﬁber tip; thus, better laser ﬁ-
bereendothelial contact, and even energy emission by the
laser, were achieved to completely shrink and occlude the
venous trunk.
Multiple punctures were then applied in the same way.
With US guidance, puncture points were placed around the
circumference of the lesions (Fig. 1; Supplementary Video).Figure 1. (A) The bare laser ﬁber (straight arrow) within a venous chann
Ultrasound during laser deployment demonstrated microbubbles formIn addition, when the laser ﬁber was so superﬁcial that the
red aiming beam was visible through the skin, the skin was
directly injected with a normal cooling solution to reduce
early skin burn. With US guidance, the catheter position
within the lesion with no back-ﬂow of blood signaled the
end point of treatment. The delivered energy was calculated
as a product of the power (in watts), pulse duration (in
seconds), and the total number of pulses. This value was
recorded in the surgical notes. On the completion of
treatment, external pressure was applied to the treated
areas with elastic bandages for 5 days. For EVMs on limb
extremities, a class III (30e40 mmHg), full-thigh, graduated
support stocking or panty hose were worn for at least 1
month at all times (except during sleep or showering) over
the course of follow-up.
Supplementary video related to this article can be found
at http://dx.doi.org/10.1016/j.ejvs.2014.02.014.
The following is the supplementary video related to this
article:Video S1Post-procedure patient care and monitoring
Ambulatory activities were encouraged after each opera-
tion. A local tape and gauze pressure dressing was applied
to the treated area for at least 2 days. The patients were
discharged after 4e6 days of observation, with instructions
to take acetaminophen or ibuprofen if needed, and to call
or return to the hospital if they had severe local pain,
numbness, chest pain, dyspnea, or skin changes. All of the
patients were followed up on an outpatient basis for
physical examinations and postoperative complaints, and
duplex ultrasonography or MRI was performed at 2 weeks,
3, 6, and 12 months, and then annually.Study endpoints and deﬁnitions
Technical success was deﬁned as a catheter or needle
entering the lesion, under US guidance, with visible back-
ﬂow of blood from the lesion, and, subsequently, theel (arrowheads) after the guiding sheath has been pulled back. (B)
ing around tip of the laser.
Table 2. Therapeutic effects.
Variable Limited Inﬁltrating Total
Mean diameter (cm) 4.9 13.4 11.81
Number of procedures 1 (36) 1 (106) 190
2 (18)
3 (4)
Number of passesa 16.6 24.3 22.83
Follow-up (mo) 23.36 24.04 23.91
Symptoms and signs
Pain 21 112 133
Unresolved 1 2 3
Resolved 17 67 84
Markedly improved 3 43 46
Heavy sensation 9 48 57
Resolved 2 27 29
Markedly improved 3 13 16
Limited range of motion 2 9 11
Resolved 1 3 4
Markedly improved 0 5 5
Hemorrhage 0 6 6
Resolved 0 6 6
Markedly improved 0 0 0
Swelling 17 88 105
Resolved 13 14 27
Markedly improved 1 41 42
Deformityb 2 27 29
Resolved 2 7 9
Markedly improved 0 11 11
Ultrasound assessment
Excellent 19 93 112
Good 13 46 59
Fair 4 15 19
a Passing of one ﬁber tip (or the number of punctures) into the
lesion.
b Morphological changes of local sessions.
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conﬁrm that the laser ﬁber was located within the venous
lumen. In this situation, the power can directly injure
endothelial cells. After treatment, the treated area was ﬁl-
led with microbubbles, and no blood was drained out afterFigure 2. Magnetic resonance imaging demonstrates the treated lesion
the procedure; (B) 1 year after the procedure.multiple punctures around the lesion by US guidance.
Clinical success was deﬁned as resolution or marked
improvement of the presenting symptoms according to the
patient. The subjective improvement of symptoms was
further assessed simultaneously using objective evidence of
improved clinical signs, including a reduction in the size of
the lesion, decreased general swelling, or improved range
of motion of the joint. Minor complications were deﬁned as
complications requiring no therapy, or minimal therapy with
no consequences. Major complications were deﬁned as
complications requiring therapy, an increased level of care,
or permanent adverse sequelae. Imaging studies were
analyzed by one radiologist and one surgeon. Duplex US
was used to assess blood ﬂow within a lesion: complete
cessation of ﬂow at the treated area was deﬁned as
“excellent”; almost-complete cessation, but with some
suspicion along draining veins was deﬁned as “good”. A
drastic reduction, but with substantial evidence, of residual
venous ﬂow of the treated area was deﬁned as “fair”. Pe-
riodic follow-up evaluations of the treatment results were
made every 6 months by the multidisciplinary team.
RESULTS
Patient characteristics
One hundred and sixty-four patients (86 women/girls [53%]
and 78 men/boys [46%]) aged 1.5e68.0 years (mean age
20.78 years) who underwent EVLA over a 71-month period
were retrospectively evaluated in this study.
Therapeutic effects
Percutaneous access and intralesional placement of laser
ﬁbers were achieved in all of the patients. All patients
tolerated the procedure well and recovered uneventfully
(Supplementary Fig. 1). They were encouraged to return to
ambulatory activities, normal daily activities, and work at 1,
3, and 10e14 days, respectively, after the procedure.
Depending on the severity of the lesions, the entire pro-
cedure lasted 30e100 minutes (mean 45 minutes). EVLAsegments became ﬁbrose, and were difﬁcult to identify. (A) Before
562 G. Liu et al.resulted in treated vessel occlusion by 2 weeks of follow-up
in all cases, deﬁned as no ﬂow detectable on duplex US
investigation.
The postoperative clinical classes of the patients are
shown in Table 2. The symptoms of all of the patients were
signiﬁcantly improved between 2 weeks and 24 months,
except for one patient who had a large number of phle-
boliths and continued to suffer pain within 2 months of
follow-up. One patient with ﬁnger lesions selected an open
procedure for slight pain alleviation after a second laser
ablation. At the 6e9-month follow-up visit, treated vessel
occlusion was substantial (>50% reduction in diameter); at
1 year and beyond, the lesions existed as minimal residual
ﬁbrous cords with no detectable ﬂow (Fig. 2). After a mean
follow-up of 23.91 months, no patient suffering pain,
hemorrhage, or limited range of motion had returned with
recurrent symptoms after initial successful treatment
(resolved). After the same follow-up period, the recurrence
rates of patients with sensation, swelling, and deformity
problems were 6.89% (two of 29), 7.41% (two of 27) and
11.11% (one of nine), respectively.
For complaints related to swelling, cosmetic outcomes
(deformity), and pain, the clinical success rates were 65.71%
(65 of 105), 68.97% (20 of 29), and 97.74% (130of 133),
respectively (Table 2). All the patients had a US scan at the
ﬁnal visit. Upon duplex US imaging, 112 (59%; 19 limited
EVMs and 93 inﬁltrating EVMs) treated lesions were clas-
siﬁed as “excellent”, 59 (31%; 13 limited EVMs, 46 inﬁl-
trating EVMs) were “good”, and 19 (10%; four limited EVMs,
15 inﬁltrating EVMs) were “fair”.Complications
Pain, ecchymosis, induration, and phlebitis were the com-
mon adverse events associated with EVLA, but they were
self-limiting. In the early period after EVLA, ecchymosisdor
discoloration beneath the skin along the course of the
treated veinsdwas experienced in 22 procedures (11.58%),
but it usually abated within 2e4 weeks. The size of the
original mass decreased signiﬁcantly, leaving a hard texture.
Two patients who had numerous phleboliths were still
experiencing pain within 6 months of follow-up, so we
suggested further surgical therapy. One young patient suf-
fered a right common peroneal nerve injury due to heat
damage, and showed foot drop and sensory loss in the right
lower limb for 6 months.
Only 19 patients required treatment with over-the-
counter analgesics (ibuprofen) for 1e2 weeks. Five
percent of the procedures resulted in indurations, but no
case required further treatment. Spot skin burn injuries
occurred in one patient (0.53%) and resolved in 2e4 weeks.
No other potential minor or major complications, such as
allergic reactions or hematomas developed, and all of the
abovementioned minor complications resolved without
sequelae. Ecchymosis along the course of the treated seg-
ments usually abated in 2 weeks in affected patients.
Thrombus-like indurations over the treated lesions with
slight or moderate pain resolved in 3e6 weeks. Paresthesiain the treated area was noted in 15 procedures (7.89%), and
abated in 1e2 months. There were no other minor or major
complications such as thrombosis, pulmonary embolism, or
systematic allergic reactions.DISCUSSION
Previous studies have suggested that laser treatment of VM
is, in fact, the method of choice in some settings owing to
its high success rate and very low incidence of complica-
tions when employed properly.14 However, the sample sizes
have been relatively small, and studies have only been
conducted over the short term. In this study, more than 160
patients were recruited, and the effectiveness of laser
ablation in the treatment of congenital EVMs was assessed.
Our success rate in lesions was 97.74% for pain relief and
65.71% for swelling. These results were comparable with
the 100% clinical success obtained in Sidhu et al.’s series on
laser treatment.14 The response to laser ablation in patients
with EVMs depends on the size of the incompetent veins
and muscle involvement. Our outcomes showed excellent
results in limited malformations of small and moderate size,
whereas the progression and growth of malformations of
greater size, especially malformations with muscle involve-
ment, could only be controlled as their eradication was
difﬁcult to achieve.
Owing to the characters of embryonic differentiation in
VM endothelial cells, inappropriate stimulation may accel-
erate the development of the disease. Therefore, optimal
treatment should destroy endothelial cells, not injure them.
To date, two theories have been proposed to be directly
involved in the action of laser ablation, one of which is
bubble steam theory, Intravenous temperatures during
EVLA have conﬁrmed that the peak temperatures at the
ﬁber tip exceed 1,200 C, and continuous temperatures of
at least 300 C are maintained in the ﬁring zone during the
whole process.12 The phenomenon of turbulent bubbles
formed at the laser tip during the application of energy was
ﬁrst described by Proebstle et al.,15 who noted that
destructive steam bubbles cause thermal injury to the
venous endothelium when the steam contacts the vein wall,
resulting in thrombotic occlusion of laser-treated vessels.15
The second theory involves the idea of direct contact. Post-
EVLA pathological specimens have shown severe transmural
tissue damage, troughing deformities, and carbonization
along the path of laser and wall contact, implying the pri-
mary mechanism of action of EVLA is thermal injury medi-
ated by direct contact between the laser and the vessel
wall.10e12 As it is known that vein walls in EVMs are
abnormal owing to the effect of embryonic differentiation,
quickly burning through the laser can also damage endo-
thelial cells, although some theoretical data are lacking.
Based on the two theories, in this study bubbles were
applied as an indicator to adjust the laser power. If the
bubbles ﬁlled the lesions, we considered that the energy
was enough and that the laser ﬁber should be retracted.
During the procedure we applied mild compression, which
may have promoted a thorough destruction of endothelial
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and did not develop a standard compression because the
lesions were irregular and control of the compression was
difﬁcult. If the lesion was not deep, we could feel the
production of steam bubbles when the laser ﬁber contacted
the lesion directly; as such, we think enough compression
was applied in this situation. The choice of wavelength,
energy level, and pulse duration of the laser exposure were
all related to the type and size of the target vessels and
tissue conduction. Previous researchers have used only 3e
10 W.14 We suggest that it may be necessary to use 10e
13 W. With the experience gained in this study, we realized
that higher laser energy levels could destroy the malformed
veins more thoroughly, which might have resulted in a
lower recurrence rate.
It should be noted here that the effect of each EVLA is
not always ideal, and there are poorer results in a number
of symptoms, particularly with regard to deformity (31.34%,
9 of 29) and swelling (34.39%, 36 of 105) .In this situation,
other options were recommended, such as surgery, abso-
lute alcohol, for example. Among the patients in whom
treatment was deemed a technical success, more than half
(52.78%, 19 of 36; Table 2) of treated vessels in the limited
malformations were shown by US to have disappeared. Very
pleasing results were obtained with the localized type; in
most of these lesions, palliation was achieved after only one
procedure. Patients with diffuse lesions required repeat
sessions in untreated areas with relief of symptoms. For
those lesions containing a large number of phleboliths, the
efﬁcacy of laser treatment was not satisfactory because
laser treatment alone could not clear the phleboliths. Thus,
a combination of lasers and surgery may be a better option.
For those lesions with muscle involvement, as long as the
symptoms improved we did not recommend further treat-
ment because excessive EVLA leads to muscle ﬁbrosis,
which may cause discomfort when walking. The best results
were obtained in patients with pain, hemorrhage, and a
limited range of motion. Amongst patients experiencing
heavy sensation, swelling, and deformity, we found, during
follow-up, ﬁve to have recurrent symptoms. A possible
explanation for this is that remnants of endothelial cells still
have the capacity to regenerate. In this study, the follow-up
time was not long; it is likely that more recurrent cases will
be found as a result of longer follow-up. The laser treatment
was considered as a palliative, minimally invasive treatment
and not as an option for cure; therefore, if the patient did
not feel better after this treatment, other treatments (sur-
gery or sclerotherapy) were recommended.
With the help of US, the ﬁber tip can reach the targeted
parts of the lesions quickly and accurately, making the
procedure safer and more efﬁcient. In this series, US guid-
ance was used not only for conﬁrming the laser position,
but also to monitor the formation and distribution of
microbubbles in real time in order to choose the appro-
priate level of power with which to treat individually the
selected venous channels (which varied in size), and to
decrease the risk of nontarget thrombosis. However, US is
not the gold standard for post-EVLA assessment, but it is aneasily accessible, inexpensive tool that allows the assess-
ment of blood ﬂow velocity. If US examination of the lesion
demonstrated reduced blood ﬂow, the treatment was
considered to be effective It is worth mentioning that even
though a nerve trunk can be discerned by US, serious nerve
injury may occur owing to the heat conduction effect. In
this series, one patient suffered a right common peroneal
nerve injury due to thermal damage along the pulsed laser
incisions, and showed foot drop and sensory loss. In our
experience, when lesions were involved in important nerve
tissues, directing the laser tip into the nerve trunk should
be avoided; our previous cases (proximity to brachial
plexus) showed that directing the laser a short distance
away from the nerve trunk can also obtain a good result.13
Otherwise, sclerosant (lauromacrogol) was recommended
as a good option.
CONCLUSIONS
In this series of patients treatedwith US-guided laser ablation
for EVMs, there was improvement or resolution of the pre-
senting symptoms inmost patients, and a decrease in the size
of all of the lesions, with quite low morbidity. Although this
approach only allows moderation of the progression and
reduction of the size of lesions with lower ﬂow rates, our
experience suggests that EVLA is an effective treatmentwhen
patients are selected appropriately. Future prospective
studies, including more standardized clinical, photographic,
and imaging follow-up data, will be useful in further deﬁning
the role of this technique in the treatment of EVMs.
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